Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IgGAM is a preparation containing human immunoglobulins G, A, and M. It is used as an adjuvant therapy in severe infections such as sepsis and peritonitis. The drug exerts broad immunoregulatory effects by both enhancing immune responses (hyperinflammation) and suppressing excessive inflammation (hypoinflammation). Its mechanism of action includes pathogen elimination, endotoxin neutralization, modulation of the complement system to prevent tissue damage, and regulation of cytokine production. Clinical studies have shown that administration of IgGAM can improve survival in patients with severe infections like peritonitis[7]. Immunoglobulins are natural human proteins with established clinical use since the 1980s.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Immunoglobulin G, A, and M.